Telix Reports US$186M Q1 Revenue, Up 62% YOY
Seeking Alpha / 1 minute ago 1 Views
Telix Pharmaceuticals reported strong Q1 2025 revenue of $186 million, up 62% year-on-year, driven by Illuccix® sales and RLS Radiopharmacies acquisition.
Seeking Alpha / 1 minute ago 1 Views
Comments